News Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Investor Alerts Year All Years 2023 2022 2021 2020 2019 2018 2017 Keywords Go Advanced Search Search Search Headlines Only From To Asset Types Photos Video Audio Documents Events Standard May 30, 2023 Immunic to Participate in Scientific and Investor Conferences in June May 17, 2023 Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis May 11, 2023 Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update May 9, 2023 Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2023, and Provide Corporate Update May 6, 2023 Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action May 4, 2023 Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders Apr 27, 2023 Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D. Apr 26, 2023 Immunic to Participate in Investor and Scientific Conferences in May Apr 5, 2023 Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis Mar 2, 2023 Immunic to Participate in Investor and Scientific Conferences in March Feb 23, 2023 Immunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update Feb 22, 2023 Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023 Feb 16, 2023 Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update Feb 9, 2023 Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need Jan 25, 2023 Immunic to Participate in Scientific and Investor Conferences in February Nov 17, 2022 Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential Nov 10, 2022 Immunic to Participate in Investor and Scientific Conferences in November and December Nov 3, 2022 Immunic, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update Oct 27, 2022 Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update Oct 20, 2022 Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate Oct 10, 2022 Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing Oct 4, 2022 Immunic to Participate in Scientific and Industry Conferences in October Sep 20, 2022 Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects Sep 1, 2022 Immunic, Inc. to Participate in Investor Conferences in September Aug 16, 2022 Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium Show 5102550100 per page«1234567»
